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Synchronous occurrence of mantle cell lymphoma (MCL)
and gastric cancer in the same patient has not yet been
reported in the English literature. MCL comprises 2.5 - 7% of
non-Hodgkin's lymphomas and is characterized by a poor
prognosis with a median survival probability of 3 - 4 years in
most series. A 62-year-old man was referred to our hospital
for evaluation of an abnormal gastric lesion. The endoscopic
finding was compatible with type IIc early gastric cancer
(EGC) in the middle third of the stomach, and a biopsy of
the lesion proved to be carcinoma. Radical total gastrectomy
with splenectomy and Roux-en-Y esophagojejunostomy were
performed. The resected specimen revealed two grossly
separated lesions. Postoperative histological examination
reported both adenocarcinoma and MCL. Immunohisto-
chemical staining showed positivity for CD5, CD20, and
cyclin D1 in the infiltrated lymphoid cells. MCL is an
aggressive non-Hodgkin's lymphoma, and the current treatment
approach is still unsatisfactory. Further advancements in the
understanding of the synchronous occurrence of both diseases,
and more efforts on investigations of treatment are needed.
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INTRODUCTION
Multiple occurrences of primary neoplasms is
relatively well known, but simultaneous occur-
rence of malignant tumors of different histologic
types is rare. Specifically, synchronous manifesta-
tion of primary adenocarcinoma and MCL within
the same stomach has never been reported. MCL
is a well-recognized subtype of B-cell lymphoma
associated with a very poor prognosis.
1-3 The
incidence of MCL is approximately 2 - 3/100,000/
year, which represents approximately 5 - 10% of
all lymphoma cases in North America and
Europe.
1,4,5 MCL comprises 2.5 - 7% of non-Hodg-
kin's lymphomas (NHLs) and involves the gastro-
intestinal tract in up to 30% of cases.
4-6 Important
findings about the molecular biology and genetics
of MCL have recently been made.
7,8 However,
MCL is still characterized by a poor prognosis due
to its aggressive clinical course. The median sur-
vival of the disease is only 3 years, and only 10-
15% of the patients are long-term survivors.
1-3,8,9 A
satisfactory standard treatment for a cure has not
yet been established. Furthermore, little is known
about the coexistence of gastric mantle cell
lymphoma and gastric adenocarcinoma. We
hereby report a rare case of synchronous gastric
adenocarcinoma and MCL detected incidentally in
the area of the middle third of the stomach.
CASE REPORT
A 62-year-old man presented with an abnormal
gastric mucosal lesion (Fig. 1) during a routine
check-up for evaluation of generalized weakness.
The lesion was diagnosed as gastric cancer by a
gastrointestinal endoscopy. He had been previo-
usly diagnosed with diabetes mellitus, Alzheimer's
disease, and renovascular hypertension. He had
no symptoms associated with the gastrointestinal
tract and no history of a Helicobacter pylori
infection. Superficial lymph nodes were not
palpable. All other physical examinations were
unremarkable.
A complete blood cell count showed hemoglo-
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bin 15.4 g/dL, hematocrit 44.4%, platelet 249,000/
L, and white blood corpuscle 8,500/ L. On a μ μ
tumor marker study, alpha fetoprotein (AFP) was
1.8 ng/mL, carcinoembryonic antigen (CEA) was
4.9 ng/mL, and carbohydrate antigen (CA) 19 - 9
was 5.5 U/mL. Other laboratory findings were
within normal limits. Upon endoscopy, there were
two mucosal abnormalities. One abnormality was
a relatively well demarcated lesion, 3.5 cm in size,
with an irregular margin just above the gastric
angle. Another 3 cm, whitish, and elevated lesion
with central ulceration was noted on the greater
curvature side of a body. Microscopic examination
of an endoscopic biopsy specimen of the first
lesion revealed a carcinoma, and the latter re-
vealed dysplasia. Simultaneously performed ab-
dominal computed tomography showed slightly
enlarged perigastric lymph nodes without distant
metastasis. Ultrasonography and a whole body
bone scan showed no significant findings.
We performed a radical total gastrectomy with
a splenectomy and Roux-en-Y esophagojejuno-
stomy. Macroscopically, there were two flat and
oval shaped, plaque-like lesions on the lesser and
greater curvature of the body. The sizes of each
lesion were 3.5 cm by 3.0 cm and 3.0 cm by 2.5 cm,
respectively (Fig. 2). Microscopically, the smaller
lesion in the greater curvature was tubular
adenoma with well differentiated adenocarcinoma
confined to gastric mucosa (Fig. 3). There were no
lymph node metastases of the carcinoma in any of
the 39 lymph nodes. The larger lesion of the lesser
curvature showed multiple nodular proliferations
of small lymphoid cells mainly in the mucosa
with focal submucosal extension (Fig. 4). MCL
Fig. 2. Gross findings of the resected stomach and its
histological mapping.
Fig. 1. Endoscopic images of the stomach showing two
mucosal abnormalities on the lesser and greater curva-
tures.
Fig. 4. Multiple, round lymphoid aggregates are noted in
the mucosa and submucosa (× 10, H&E stain).
Fig. 3. The stomach shows well differentiated adenocar-
cinoma at the superficial portion of the mucosa (× 40,
Hematoxylin & Eosin (H&E) stain).Synchronous Adenocarcinoma and Mantle Cell Lymphoma of the Stomach
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cells were found in 27 out of the 39 retrieved
lymph nodes. Immunohistochemical staining of
the small lymphoid cells showed positive reaction
for CD5, CD20, and cyclin D1 (Fig. 5) and nega-
tive reaction for CD3 and MT1. These findings
were compatible with synchronous manifestation
of EGC IIc (Stage Ia) and MCL (stage III). The
patient made an uneventful postoperative rec-
overy and did not receive any adjuvant chemo-
therapy due to his refusal.
DISCUSSION
Although many reports have been published
about multiple carcinomas of the stomach, few
have reported the coexistence of gastric carcinoma
and gastric malignant lymphoma.
10-12 There has
especially been no report about synchronous pri-
mary adenocarcinoma and MCL of the stomach.
Only a few cases of synchronous adenocarcinoma
and MCL of the colon have been reported in
western countries.
13,14 The incidence of colorectal
cancer in western countries has been high, even
though the tumorigensis of adenocarcinoma and
MCL are different, complex, and multifactorial.
Interestingly, the present synchronous occurrence
of gastric adenocarcinoma and MCL in the same
stomach seems to be by chance because the in-
cidence of gastric adenocarcinoma in Korea is
higher than that in western countries.
MCL was individualized years ago under sev-
eral different names. The term MCL was proposed
for unification of morphologic, immunologic, and
molecular data.
15 The term MCL represents a
subtype of lymphomas previously classified as
centrocytic lymphoma by Kiel classification,
16
intermediate cell lymphoma by Berard et al.,
17 and
diffuse small-cleaved cell lymphoma in the
Working Formulation.
18 In contrast to other lym-
phoma subtypes, the etiology and pathogenesis of
MCL are not well known. Interestingly, one report
suggested that trisomy 3 might be a common
chromosomal abnormality in lymphomatous
polyps of the mantle cell type.
19 The median age
of patients is 54-68 years, and the male to female
ratio is 2-3:1 at diagnosis.
9,20 Approximately 95%
of patients present with an advanced stage (Ann
Arbor stage III-IV).
5,8,20 In the patient of this
report, the age, gender, and stage appear to be
similar to patients of previous reports.
5,8,9,20
The symptoms and signs of gastrointestinal
MCL include abdominal pain, diarrhea, hemato-
chezia, nausea, vomiting, weight loss, and fatigue.
Gastrointestinal involvement may occur in 10 -
30% of patients either at presentation or during
the course of the disease.
4,6,9 Upper gastrointesti-
nal involvement was more common than in-
volvement of the colon.
9 A study of endoscopic
findings of the upper and lower gastrointestinal
Fig. 5. The lymphocytes are small and
monotonous (H&E, × 200), which are
positive for CD20, CD5, and cyclin-D1
(× 400). These findings are consistent
with the diagnosis of mantle cell lym-
phoma.Yong Il Kim and Min Young Koo
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tract are as follows (exclusive of normal finding):
inflammation (29.2%, 0%); nodules and polyps
(50%, 92.6%); ulcer (12.5%, 3.7%); thickened wall
(4.2%, 3.7%); and mass (4.2%, 0%).
6 Extra-nodal
involvement is found in approximately 90% of
cases; hence, diagnoses at advanced Ann Arbor
stages III or IV are frequent.
5,9,10 B-symptoms are
present in less than 50% of the cases.
2,8
Diagnosis of MCL is able to be more accurately
made due to the advancement in technology of
immunology and molecular genetics. The Interna-
tional Lymphoma Study Group (ILSG) published
'Revised European American Classification of
Lymphoid Neoplasm' integrating all the mor-
phologic, immunologic, genetic, and molecular
biologic information. Thus, MCL was classified as
one of the independent subtypes of 11 peripheral
B-cell lymphomas.
21 Differential diagnosis from
other lymphomas by morphologic findings alone
is difficult;
22 therefore, immunohistochemical
staining is necessary for diagnosis. MCL is
typically positive for CD5, CD19, CD20, CD22,
CD79a, and cyclin D1. MCL is usually negative
for CD10 and CD23.
1,8,23,24 CD5 is particularly
helpful in differential diagnosis with follicular
lymphoma. CD5 is positive for MCL and small
lymphocytic lymphoma. CD5 is negative for
follicular lymphoma.
1,8 The most valuable marker
for the diagnosis of MCL is cyclin D1. Overex-
pression of cyclin D1 indicates bcl-1 gene
rearrangement, which is due to the occurrence of
t (11;14) in 70% of cases.
23,24 In our case, immuno-
histochemical staining showed positive results for
CD5, CD20, and cyclin D1 and negative results for
CD3 and MT1. In patients with coexistent
lymphoma and carcinoma, two neoplasms are
usually located separately. The lymphoma is
usually advanced, and carcinoma is well-differ-
entiated.
12 Interestingly, in our case the lesions
were in the same situation as those in the cited
reports. Because MCL has the poorest long-term
survival, a wait- and-see strategy is not an
appropriate approach. Different chemotherapeutic
regimens achieve overall survival of 52 months
with complete remission in 20 - 40% of patients.
2,5,25
Therefore, we planned to use adjuvant
chemotherapy focused on the MCL because there
was no necessity for chemotherapy in EGC.
Unfortunately, the presented patient refused to
receive any adjuvant chemotherapy due to
personal reasons.
Important clinical prognostic factors of MCL
that have been revealed in previous studies are
poor performance status, advanced clinical stage,
splenomegaly, anemia, infiltration of bone mar-
row and peripheral blood, transformation to the
blastic variant, mitotic index > 2.5, p53 mutations,
elevation of lactate dehydrogenase (LDH) level,
and age.
20 However, the prognosis of patients
with synchronous gastric adenocarcinoma and
MCL has yet to be clarified due to the lack of any
long-term follow-up observation.
Synchronous development of these two tumors
is one of the most challenging problems in diag-
nosis and treatment. Since there are no typical
endoscopic findings or gross findings of gastric
adenocarcinoma different from other lymphomas,
synchronous carcinomas may be misinterpreted as
multifocal separated lesions of lymphoma because
of their macroscopic resemblance. Therefore,
gastric lymphoma patients should be carefully
examined by endoscopy. Suspicious areas must be
biopsied considering the possibility of coexisting
adenocarcinomas. Moreover, considerable im-
provements have been accomplished in the
understanding and therapeutic approaches of the
disease. However, the treatment outcome is still
highly unsatisfactory. Therefore, new therapeutic
strategies and follow up studies are needed to
improve the clinical outcome of synchronous
gastric adenocarcinoma and MCL.
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